Arachnoiditis

Myodil

[Letter Nexus Dec 2006] Arachnoiditis Awareness

Chemically Induced Adhesive Arachnoiditis Sufferers of Australia (CIAASA)

There are two forms of Arachnoiditis, Adhesive Arachnoiditis and Arachnoiditis.  THOUSANDS of Australians are living in chronic pain after their spines were injected with a dye (Pantopaque / Myodil) in an X-ray procedure that was used for 42 years.  The dye enabled doctors to see the spine more clearly in a type of X-ray called a Myelogram and was used between 1945 and 1988.  Victims of the dye's effects can suffer burning back pain, shooting pains in limbs, deep muscle pains in back and limbs, spasms and twitches, burning feet, Joint pains, numbness and tingling sensations, seizures and paralysis, visual impairment and feelings that insects are crawling on their skin.  Known as Adhesive Arachnoiditis, the disease is caused by the inflammation and fusion of the nerves and membranes of the spinal cord. The condition can take up to 20 years to develop.  Unfortunately most Adhesive Arachnoiditis and Arachnoiditis is Medically Acquired.  If you have had a Myelogram in the past and you have unexplained health issues now, then there is a chance that you have Adhesive Arachnoiditis. http://www.aasqa.info/

This website was originally created to help find, then assist those who have acquired Adhesive Arachnoiditis from having had a Myelogram, but we now realise that many Medical Procedures (such as Epidurals, Cortisone Injections and basically any Spinal injection) have the potential to create Arachnoiditis.   Although we focus on Adhesive Arachnoiditis we are also looking to be of help to all who have acquired Arachnoiditis from any Medical Procedure. http://www.aasqa.info/

What is not commonly known is that the developers of the "dye", Kodak, knew it would cause CIAA before they licensed it (May 1944). Today, there are 80 medical conditions or symptoms that have been recognised as a "cause or effect" of exposure to this "too toxic" chemical dye (NIH, 1994). Many of the drugs now used to treat these secondary conditions or symptoms of CIAA have been developed or patented by those who developed the original formula (for some, with slight changes of said formula; later, for instance, Myodil by GlaxoSmithKline).
    I will go on the record to state the following: the developers of the diagnostic radiographic contrast medium knew before they applied for an NDA (new drug application) that it would cause arachnoiditis, and furthermore were aware of some of the other found reactions to this "dye" that were also not reported to the authorities.
    I will go further and also place on the record that the collection of "secret studies" shows such; however, none was ever submitted to the FDA when applying for the NDA. Copies of all these "secret studies" are held in a bank safe on my behalf; these can be made available to any person who is willing to publicly publish such. [Letter Nexus Dec 2006] Arachnoiditis Awareness